Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.164
https://www.valueinhealthjournal.com/article/S1098-3015(13)02069-X/fulltext
Title :
Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02069-X&doi=10.1016/j.jval.2013.08.164
First page :
A350
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
151